RE: Trinity Delta22 Jul 2020 12:37
Trinity Delta view: The size of the fund raise provides sufficient resources for Scancell to pursue the clinical opportunities it has. We detailed these in our recent Outlook note (May 2020) and outlined our belief that Scancell was under-funded relative to the size and scope of these clinical opportunities. In line with our policy, we suspend our valuation and forecasts with the aim of reinstating updated values as soon as practicable. For context, our previous valuation was £72.4m, equivalent to 15.6p a share. We reiterate that there are various likely share catalysts over the coming year including: further AvidiMab collaborations, the SCIB1 UK/US trial being underway, and the initiation of enrolment of the first SCIB2 and Moditope studies.
SCIB2 as well ................. bring it ON ....